<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990509</url>
  </required_header>
  <id_info>
    <org_study_id>2009-173</org_study_id>
    <nct_id>NCT00990509</nct_id>
  </id_info>
  <brief_title>Albumin for Intracerebral Hemorrhage Intervention</brief_title>
  <acronym>ACHIEVE</acronym>
  <official_title>Albumin for Intracerebral Hemorrhage Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and bad, the medication Albumin&#xD;
      has on subjects who have experienced a type of stroke known as an intracerebral hemorrhage&#xD;
      (ICH). An ICH is when spontaneous bleeding into the brain occurs due to fragile blood&#xD;
      vessels.&#xD;
&#xD;
      This research is being done because currently there is no effective treatment for ICH.&#xD;
      However, study investigators believe that Albumin, the medication being tested in this study,&#xD;
      is safe and may help improve patient recovery from ICH over time.&#xD;
&#xD;
      Subjects will be enrolled in the study for a total of 90 days. Following enrollment, subjects&#xD;
      will be randomized to receive 3 daily injections of either Albumin or Placebo (liquid with no&#xD;
      drug), and will receive 3 brain MRI scans (with and without contrast), as described below.&#xD;
&#xD;
      All subjects will be monitored continuously through 96 hours after enrollment (5 days) in the&#xD;
      Georgetown ICU. Blood tests and clinical evaluations of neurological status, consisting of&#xD;
      questions about subjects' functional abilities and medical history, will occur in the&#xD;
      Georgetown ICU once every 24 hours through post-enrollment Day 5. Additionally, subjects will&#xD;
      receive daily chest x-rays, and daily EKGs (exams that monitor how your heart is doing by&#xD;
      placing electrodes, or small monitors, on your skin in specific locations).&#xD;
&#xD;
      Similar clinical evaluations will occur at Day 30 and Day 90. Should subjects be discharged&#xD;
      at these time points, day 30 assessments will occur over the phone, and day 90 assessments&#xD;
      will occur in-person at Georgetown University Medical Center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to determine the safety and explore the efficacy of human albumin as a neuroprotective&#xD;
      (or cytoprotective) agent for the treatment of acute primary supratentorial ICH. Albumin&#xD;
      therapy has been shown to be cytoprotective in animal studies of both ischemic stroke and&#xD;
      intracerebral hemorrhage, and in a phase II human study in ischemic stroke.&#xD;
&#xD;
      To date no acute intervention (beyond supportive medical care) has been identified to improve&#xD;
      outcomes in patients with primary ICH. Neuronal injury from a primary ICH is due not only to&#xD;
      the space occupying effects of the hemorrhage but also due to the development of edema and&#xD;
      toxicity from blood breakdown products in the subacute phase. Cytoprotective strategies&#xD;
      targeted to limit blood brain barrier (BBB) breakdown and edema formation hold promise as&#xD;
      treatment strategies to limit this injury.&#xD;
&#xD;
      A number of MR imaging outcome markers demonstrating a potential neuroprotective effect&#xD;
      include measures of hematoma volume, perihematomal edema, and blood brain barrier disruption.&#xD;
      The term &quot;hyperintense acute injury marker&quot; (HARM) has been proposed to describe the&#xD;
      radiologic finding of hyperintense signal within the cerebrospinal fluid spaces visualized on&#xD;
      post-contrast fluid attenuated inversion recovery (FLAIR) MRI in patients with acute ischemic&#xD;
      stroke. HARM has the potential to serve as a marker of blood brain barrier disruption in&#xD;
      patients with primary ICH. The current study will involve serial MR imaging in ICH patients&#xD;
      randomized to placebo vs. albumin to assess whether there are differences in the frequency of&#xD;
      HARM and perihematomal edema in the albumin treated patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment was stopped due to low recruitment and the PI's move to a different institution.&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Hyperintense Acute injuRy Marker (HARM)</measure>
    <time_frame>Day 5 MRI</time_frame>
    <description>Hyperintense Acute injuRy Marker (HARM) characterizes the frequency and severity of blood brain barrier disruption. Mean HARM is assessed on the post-contrast study using a previously developed 5 point scale (0 to 5).). A score of 0 indicates no HARM, whereas a score of 5 indicates diffuse and generalized HARM. 11 of 14 participants received a Day 5 MRI. HARM reads could only be performed on 4 of the 7 placebo subjects due to insufficient sequences or presence of subarachnoid blood. Mean HARM score is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Safety of Albumin Administration in Primary ICH</measure>
    <time_frame>Through Day 90 following enrollment</time_frame>
    <description>Serious adverse events. Specific safety outcomes assessed: frank pulmonary edema as visualized on chest X-Ray, congestive heart failure, neurological deterioration (4-point worsening on NIHSS), death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Intracerebral Hemorrhage (ICH) Volume</measure>
    <time_frame>Day 5 MRI</time_frame>
    <description>11 of 14 participants received a Day 5 MRI. Mean ICH volume based on 11 participants is presented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.</description>
    <arm_group_label>Albumin</arm_group_label>
    <other_name>BUMINATE 25%, Albumin (Human)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain MRI with and without contrast</intervention_name>
    <description>All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>1.5T Siemens Symphony MRI.</other_name>
    <other_name>3T Siemens Verio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary supratentorial ICH&#xD;
&#xD;
          -  &lt; 48 hours from symptom onset&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Signed informed consent obtained from the patient or patient's legally authorized&#xD;
             representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ICH volume &lt; 5 cc&#xD;
&#xD;
          -  Glasgow Coma Scale &lt; 6&#xD;
&#xD;
          -  Surgical evacuation anticipated&#xD;
&#xD;
          -  Pre-existing medical, neurological or psychiatric disease that would confound the&#xD;
             neurological, functional, or imaging evaluations&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Hemodynamic instability (SBP &lt; 100 mmHg, &gt; 200 mmHg)&#xD;
&#xD;
          -  Current participation in another experimental treatment protocol&#xD;
&#xD;
          -  Renal impairment with GFR &lt; 30 or Creatinine &gt; 2.0&#xD;
&#xD;
          -  History of or known allergy to albumin&#xD;
&#xD;
          -  History of or known severe allergy to rubber latex&#xD;
&#xD;
          -  Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6&#xD;
             months. (An episode of congestive heart failure is any heart failure that required a&#xD;
             change in medication, diet or hospitalization)&#xD;
&#xD;
          -  Acute myocardial infarction in the last 6 months&#xD;
&#xD;
          -  Elevated serum troponin level on admission &gt; 0.1 mcg/L&#xD;
&#xD;
          -  Known valvular heart disease with CHF in the last 6 months&#xD;
&#xD;
          -  Known (or in the investigator's judgment) existence of severe aortic stenosis or&#xD;
             mitral stenosis&#xD;
&#xD;
          -  Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG),&#xD;
             valve replacement surgery) in the last 6 months&#xD;
&#xD;
          -  Suspicion of aortic dissection on admission&#xD;
&#xD;
          -  Acute arrhythmia (including any tachy- or bradycardia) with hemodynamic instability on&#xD;
             admission (systolic blood pressure &lt; 100 mmHg).&#xD;
&#xD;
          -  Findings on physical examination of any of the following: (1) jugular venous&#xD;
             distention (JVP &gt; 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting&#xD;
             tachycardia (heart rate &gt; 100/min) attributable to congestive heart failure; (4)&#xD;
             abnormal hepatojugular reflux; (5) lower extremity pitting edema attributable to&#xD;
             congestive heart failure or without apparent cause; (6) bilateral rales; and/or (7) if&#xD;
             a chest x-ray is performed, definite evidence of pulmonary edema, bilateral pleural&#xD;
             effusion, or pulmonary vascular redistribution.&#xD;
&#xD;
          -  Current acute or chronic lung disease requiring supplemental chronic or intermittent&#xD;
             oxygen therapy.&#xD;
&#xD;
          -  Prosthetic heart valves&#xD;
&#xD;
          -  Contraindication to MRI (metal implant, etc.)&#xD;
&#xD;
          -  Documented left ventricular ejection fraction &lt; 35%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chelsea Kidwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Chelsea Kidwell, M.D.</investigator_full_name>
    <investigator_title>Professor of Neurology; Medical Director, Georgetown University Stroke Center</investigator_title>
  </responsible_party>
  <keyword>Primary ICH</keyword>
  <keyword>Albumin</keyword>
  <keyword>MRI</keyword>
  <keyword>Neuroimaging outcome</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Phase II</keyword>
  <keyword>Blinded</keyword>
  <keyword>Safety</keyword>
  <keyword>Acute ICH</keyword>
  <keyword>ICH</keyword>
  <keyword>Primary acute (&lt; 48 hours) supratentorial ICH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albumin</title>
          <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albumin</title>
          <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B2" value="58.1" lower_limit="41" upper_limit="76"/>
                    <measurement group_id="B3" value="59.7" lower_limit="41" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Hyperintense Acute injuRy Marker (HARM)</title>
        <description>Hyperintense Acute injuRy Marker (HARM) characterizes the frequency and severity of blood brain barrier disruption. Mean HARM is assessed on the post-contrast study using a previously developed 5 point scale (0 to 5).). A score of 0 indicates no HARM, whereas a score of 5 indicates diffuse and generalized HARM. 11 of 14 participants received a Day 5 MRI. HARM reads could only be performed on 4 of the 7 placebo subjects due to insufficient sequences or presence of subarachnoid blood. Mean HARM score is presented.</description>
        <time_frame>Day 5 MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hyperintense Acute injuRy Marker (HARM)</title>
          <description>Hyperintense Acute injuRy Marker (HARM) characterizes the frequency and severity of blood brain barrier disruption. Mean HARM is assessed on the post-contrast study using a previously developed 5 point scale (0 to 5).). A score of 0 indicates no HARM, whereas a score of 5 indicates diffuse and generalized HARM. 11 of 14 participants received a Day 5 MRI. HARM reads could only be performed on 4 of the 7 placebo subjects due to insufficient sequences or presence of subarachnoid blood. Mean HARM score is presented.</description>
          <units>points</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient number of patients with outcome measure available for meaningful analysis as trial was stopped early. Analysis of a small number of observations would be misleading.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Safety of Albumin Administration in Primary ICH</title>
        <description>Serious adverse events. Specific safety outcomes assessed: frank pulmonary edema as visualized on chest X-Ray, congestive heart failure, neurological deterioration (4-point worsening on NIHSS), death</description>
        <time_frame>Through Day 90 following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Safety of Albumin Administration in Primary ICH</title>
          <description>Serious adverse events. Specific safety outcomes assessed: frank pulmonary edema as visualized on chest X-Ray, congestive heart failure, neurological deterioration (4-point worsening on NIHSS), death</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Intracerebral Hemorrhage (ICH) Volume</title>
        <description>11 of 14 participants received a Day 5 MRI. Mean ICH volume based on 11 participants is presented.</description>
        <time_frame>Day 5 MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intracerebral Hemorrhage (ICH) Volume</title>
          <description>11 of 14 participants received a Day 5 MRI. Mean ICH volume based on 11 participants is presented.</description>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="47.9"/>
                    <measurement group_id="O2" value="39.2" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 Days</time_frame>
      <desc>We did not collect non-serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Albumin</title>
          <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment&#xD;
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.&#xD;
MRIs will be with and without contrast will be performed at:&#xD;
Baseline&#xD;
48 hours after enrollment(approximately Day 3)&#xD;
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic Deterioration</sub_title>
                <description>The single event of neurologic deterioration documented in this study resulted in death due to respiratory failure and was adjudicated to be unrelated to the study interventions.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was an insufficient number of subjects in each treatment arm to allow for a meaningful analysis of the effects of albumin on HARM status (blood brain barrier disruption).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chelsea Kidwell, MD</name_or_title>
      <organization>University of Arizona</organization>
      <phone>(520) 626-7159</phone>
      <email>ckidwell@neurology.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

